Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Álvarez-Cermeño JC[au]:

Search results

Items: 1 to 50 of 153

1.

Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.

Mestre L, Carrillo-Salinas FJ, Mecha M, Feliú A, Espejo C, Álvarez-Cermeño JC, Villar LM, Guaza C.

Front Immunol. 2019 Jun 14;10:1374. doi: 10.3389/fimmu.2019.01374. eCollection 2019.

2.

A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosis.

Peroni S, Sorosina M, Malhotra S, Clarelli F, Osiceanu AM, Ferrè L, Roostaei T, Rio J, Midaglia L, Villar LM, Álvarez-Cermeño JC, Guaschino C, Radaelli M, Citterio L, Lechner-Scott J, Spataro N, Navarro A, Martinelli V, Montalban X, Weiner HL, de Jager P, Comi G, Esposito F, Comabella M, Martinelli-Boneschi F.

Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428. [Epub ahead of print]

PMID:
31221001
3.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
4.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C.

Mult Scler. 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844. [Epub ahead of print]

PMID:
31066634
5.

Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients.

Medina S, Sainz de la Maza S, Villarrubia N, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, Álvarez-Cermeño JC, Villar LM.

Ann Clin Transl Neurol. 2019 Jan 15;6(2):355-363. doi: 10.1002/acn3.711. eCollection 2019 Feb.

6.

Factors associated with dimethyl fumarate-induced lymphopenia.

Sainz de la Maza S, Medina S, Villarrubia N, Costa-Frossard L, Monreal E, Tejeda-Velarde A, Rodríguez-Martín E, Roldán E, Álvarez-Cermeño JC, Villar LM.

J Neurol Sci. 2019 Mar 15;398:4-8. doi: 10.1016/j.jns.2019.01.007. Epub 2019 Jan 8.

PMID:
30658226
7.

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

Malhotra S, Villar LM, Costa C, Midaglia L, Cubedo M, Medina S, Fissolo N, Río J, Castilló J, Álvarez-Cermeño JC, Sánchez A, Montalban X, Comabella M.

J Neuroinflammation. 2018 Oct 26;15(1):296. doi: 10.1186/s12974-018-1336-9.

8.

Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients.

Szejko N, Picón C, García-Caldentey J, de Yebenes JG, Alvarez-Cermeño JC, Villar LM, López-Sendón Moreno JL.

PLoS Curr. 2018 Aug 31;10. pii: ecurrents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da. doi: 10.1371/currents.hd.280c8f9f7d9fa4f7f0c883d9f8e807da.

9.

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course.

Gil-Varea E, Urcelay E, Vilariño-Güell C, Costa C, Midaglia L, Matesanz F, Rodríguez-Antigüedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, García-Merino JA, Ramió-Torrentà L, Triviño JC, Quintana E, Robles R, Sánchez-López A, Arroyo R, Alvarez-Cermeño JC, Vidal-Jordana A, Malhotra S, Fissolo N, Montalban X, Comabella M.

J Neuroinflammation. 2018 Sep 14;15(1):265. doi: 10.1186/s12974-018-1307-1.

10.

Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.

Fissolo N, Cervera-Carles L, Villar Guimerans LM, Lleó A, Clarimón J, Drulovic J, Dujmovic I, Voortman M, Khalil M, Gil E, Navarro L, Álvarez-Cermeño JC, Montalban X, Comabella M.

Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055. [Epub ahead of print]

PMID:
29985092
11.

Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients.

Casanova B, Lacruz L, Villar ML, Domínguez JA, Gadea MC, Gascón F, Mallada J, Hervás D, Simó-Castelló M, Álvarez-Cermeño JC, Calles C, Olascoaga J, Ramió-Torrentà L, Alcalá C, Cervelló A, Boscá I, Pérez-Mirallles FC, Coret F.

Neurol Sci. 2018 Aug;39(8):1423-1430. doi: 10.1007/s10072-018-3442-y. Epub 2018 Jun 7.

PMID:
29882169
12.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
13.

Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the 'hygiene hypothesis'?

Alari-Pahissa E, Moreira A, Zabalza A, Alvarez-Lafuente R, Munteis E, Vera A, Arroyo R, Alvarez-Cermeño JC, Villar LM, López-Botet M, Martínez-Rodríguez JE.

Eur J Neurol. 2018 Jul;25(7):925-933. doi: 10.1111/ene.13622. Epub 2018 Apr 15.

PMID:
29528545
14.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
15.

Clinical usefulness of prognostic biomarkers in optic neuritis.

Tejeda-Velarde A, Costa-Frossard L, Sainz de la Maza S, Carrasco Á, Espiño M, Picón C, Toboso I, Walo PE, Lourido D, Muriel A, Álvarez-Cermeño JC, Villar LM.

Eur J Neurol. 2018 Apr;25(4):614-618. doi: 10.1111/ene.13553. Epub 2018 Feb 6. Erratum in: Eur J Neurol. 2018 Oct;25(10):1303.

PMID:
29272057
16.

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, Sainz de la Maza S, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):32. doi: 10.1007/s00415-017-8679-5.

PMID:
29177546
17.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2018 Oct;24(11):1507-1510. doi: 10.1177/1352458517739137. Epub 2017 Nov 9.

18.

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, de la Maza SS, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):24-31. doi: 10.1007/s00415-017-8625-6. Epub 2017 Oct 12. Erratum in: J Neurol. 2017 Nov 24;:.

PMID:
29027004
19.

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.

Medina S, Villarrubia N, Sainz de la Maza S, Lifante J, Costa-Frossard L, Roldán E, Picón C, Álvarez-Cermeño JC, Villar LM.

Mult Scler. 2018 Sep;24(10):1317-1327. doi: 10.1177/1352458517717088. Epub 2017 Jun 27.

PMID:
28653862
20.

Multimarker risk stratification approach at multiple sclerosis onset.

Fernández-Paredes L, Casrouge A, Decalf J, de Andrés C, Villar LM, Pérez de Diego R, Alonso B, Álvarez Cermeño JC, Arroyo R, Tejera-Alhambra M, Navarro J, Oreja-Guevara C, López Trascasa M, Seyfferth A, García Martínez MA, Álvarez Lafuente R, Albert ML, Sánchez-Ramón S.

Clin Immunol. 2017 Aug;181:43-50. doi: 10.1016/j.clim.2017.05.019. Epub 2017 May 31.

PMID:
28578025
21.

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.

Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C.

Sci Rep. 2017 Mar 14;7:44377. doi: 10.1038/srep44377.

22.

Metabolomic signatures associated with disease severity in multiple sclerosis.

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar.

23.

miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands.

Quintana E, Ortega FJ, Robles-Cedeño R, Villar ML, Buxó M, Mercader JM, Alvarez-Cermeño JC, Pueyo N, Perkal H, Fernández-Real JM, Ramió-Torrentà L.

Mult Scler. 2017 Nov;23(13):1716-1726. doi: 10.1177/1352458516684213. Epub 2017 Jan 9.

PMID:
28067602
24.

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Matute-Blanch C, Río J, Villar LM, Midaglia L, Malhotra S, Álvarez-Cermeño JC, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2017 Feb 15;303:62-65. doi: 10.1016/j.jneuroim.2016.12.006. Epub 2016 Dec 18.

PMID:
28063616
25.

Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.

Órpez-Zafra T, Pavía J, Hurtado-Guerrero I, Pinto-Medel MJ, Rodriguez Bada JL, Urbaneja P, Suardíaz M, Villar LM, Comabella M, Montalban X, Alvarez-Cermeño JC, Leyva L, Fernández Ó, Oliver-Martos B.

Mult Scler. 2017 Jun;23(7):937-945. doi: 10.1177/1352458516667564. Epub 2016 Sep 9.

PMID:
27613121
26.

Neurofilament light chain level is a weak risk factor for the development of MS.

Arrambide G, Espejo C, Eixarch H, Villar LM, Alvarez-Cermeño JC, Picón C, Kuhle J, Disanto G, Kappos L, Sastre-Garriga J, Pareto D, Simon E, Comabella M, Río J, Nos C, Tur C, Castilló J, Vidal-Jordana A, Galán I, Arévalo MJ, Auger C, Rovira A, Montalban X, Tintore M.

Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Erratum in: Neurology. 2016 Nov 8;87(19):2068.

27.

[Response to treatment with interferon beta in patients with multiple sclerosis. Validation of the Rio Score].

Rio J, Rovira A, Blanco Y, Sainz A, Perkal H, Robles R, Ramio-Torrenta L, Diaz RM, Arroyo R, Urbaneja P, Fernandez O, Garcia-Merino JA, Reyes MP, Oreja-Guevara C, Prieto JM, Izquierdo G, Olascoaga J, Alvarez-Cermeno JC, Simon E, Pujal B, Comabella M, Montalban X.

Rev Neurol. 2016 Aug 16;63(4):145-50. Spanish.

28.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

29.

A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis.

Ramió-Torrentà L, Álvarez-Cermeño JC, Arroyo R, Casanova-Estruch B, Fernández O, García-Merino JA, Hernández MA, Izquierdo G, Martínez-Yélamos S, Meca J, Moral E, Olascoaga J, Prieto JM, Saiz A.

Neurologia. 2018 Jun;33(5):327-337. doi: 10.1016/j.nrl.2015.11.013. Epub 2016 Feb 10. Review. English, Spanish.

30.

Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis.

Álvarez-Cermeño JC, Muñoz-Negrete FJ, Costa-Frossard L, Sainz de la Maza S, Villar LM, Rebolleda G.

J Neurol Sci. 2016 Jan 15;360:41-4. doi: 10.1016/j.jns.2015.11.030. Epub 2015 Nov 18.

PMID:
26723970
31.

Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.

de Bock L, Fraussen J, Villar LM, Álvarez-Cermeño JC, Van Wijmeersch B, van Pesch V, Stinissen P, Somers V.

Eur J Neurol. 2016 Apr;23(4):722-8. doi: 10.1111/ene.12925. Epub 2015 Dec 26.

PMID:
26706657
32.

Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis.

Borràs E, Cantó E, Choi M, Maria Villar L, Álvarez-Cermeño JC, Chiva C, Montalban X, Vitek O, Comabella M, Sabidó E.

Mol Cell Proteomics. 2016 Jan;15(1):318-28. doi: 10.1074/mcp.M115.053256. Epub 2015 Nov 9.

33.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

34.

Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.

Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Alvarez-Lafuente R, Saiz A, Alvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M.

Mult Scler. 2016 May;22(6):741-52. doi: 10.1177/1352458515601215. Epub 2015 Sep 11.

PMID:
26362897
35.

Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS Meeting (II).

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 16;61(6):271-83. English, Spanish.

36.

[Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)].

Fernandez O, Alvarez-Cermeno JC, Arroyo R, Brieva L, Calles-Hernandez MC, Casanova-Estruch B, Comabella M, Garcia-Merino JA, Ginestal R, Izquierdo G, Meca-Lallana JE, Mendibe-Bilbao MM, Montalban X, Munoz-Garcia D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Ramio-Torrenta L, Romero-Pinel L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Grupo Post-Ectrims GP.

Rev Neurol. 2015 Sep 1;61(5):215-24. Spanish.

37.

Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis.

Ortiz MA, Núñez C, Ordóñez D, Alvarez-Cermeño JC, Martínez-Rodriguez JE, Sánchez AJ, Arroyo R, Izquierdo G, Malhotra S, Montalban X, García-Merino A, Munteis E, Alcina A, Comabella M, Matesanz F, Villar LM, Urcelay E.

PLoS One. 2015 Aug 14;10(8):e0134414. doi: 10.1371/journal.pone.0134414. eCollection 2015.

38.

A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis.

Matesanz F, Potenciano V, Fedetz M, Ramos-Mozo P, Abad-Grau Mdel M, Karaky M, Barrionuevo C, Izquierdo G, Ruiz-Peña JL, García-Sánchez MI, Lucas M, Fernández Ó, Leyva L, Otaegui D, Muñoz-Culla M, Olascoaga J, Vandenbroeck K, Alloza I, Astobiza I, Antigüedad A, Villar LM, Álvarez-Cermeño JC, Malhotra S, Comabella M, Montalban X, Saiz A, Blanco Y, Arroyo R, Varadé J, Urcelay E, Alcina A.

Hum Mol Genet. 2015 Oct 1;24(19):5619-27. doi: 10.1093/hmg/ddv256. Epub 2015 Jul 7.

PMID:
26152201
39.

Multiple sclerosis: Genetic variability affects CNS IgG production in MS.

Álvarez-Cermeño JC, Villar LM.

Nat Rev Neurol. 2015 Jun;11(6):313-4. doi: 10.1038/nrneurol.2015.55. Epub 2015 Apr 14. No abstract available.

PMID:
25868393
40.

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.

Disanto G, Adiutori R, Dobson R, Martinelli V, Dalla Costa G, Runia T, Evdoshenko E, Thouvenot E, Trojano M, Norgren N, Teunissen C, Kappos L, Giovannoni G, Kuhle J; International Clinically Isolated Syndrome Study Group.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9. doi: 10.1136/jnnp-2014-309690. Epub 2015 Feb 25.

PMID:
25716934
41.

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.

Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodríguez-Martín E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, García-Merino JA, Sánchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andrés C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sánchez A, Rovira A, Montalban X, Comabella M.

Brain. 2015 Apr;138(Pt 4):918-31. doi: 10.1093/brain/awv017. Epub 2015 Feb 13.

PMID:
25688078
42.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
43.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.

Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. Epub 2015 Jan 30.

PMID:
25581547
44.

Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.

Rodríguez-Martín E, Picón C, Costa-Frossard L, Alenda R, Sainz de la Maza S, Roldán E, Espiño M, Villar LM, Álvarez-Cermeño JC.

Clin Exp Immunol. 2015 May;180(2):243-9. doi: 10.1111/cei.12580.

45.

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, Fernández O, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec.

46.

Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.

Cantó E, Tintoré M, Villar LM, Borrás E, Alvarez-Cermeño JC, Chiva C, Sabidó E, Rovira A, Montalban X, Comabella M.

J Neuroinflammation. 2014 Nov 13;11:181. doi: 10.1186/s12974-014-0181-8.

47.

A new risk variant for multiple sclerosis at the immunoglobulin heavy chain locus associates with intrathecal IgG, IgM index and oligoclonal bands.

Delgado-García M, Matesanz F, Alcina A, Fedetz M, García-Sánchez MI, Ruiz-Peña JL, Fernández Ó, Pinto Medel MJ, Leyva L, Arnal C, Delgado C, López Guerrero JA, González-Pérez A, Sáez ME, Villar LM, Álvarez-Cermeño JC, Picón C, Arroyo R, Varadé J, Urcelay E, Izquierdo G, Lucas M.

Mult Scler. 2015 Aug;21(9):1104-11. doi: 10.1177/1352458514556302. Epub 2014 Nov 12.

48.

Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.

Villar LM, Picón C, Costa-Frossard L, Alenda R, García-Caldentey J, Espiño M, Muriel A, Álvarez-Cermeño JC.

Eur J Neurol. 2015 Aug;22(8):1169-75. doi: 10.1111/ene.12579. Epub 2014 Oct 17.

PMID:
25324032
49.

Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis.

González-López JJ, Rebolleda G, Leal M, Oblanca N, Muñoz-Negrete FJ, Costa-Frossard L, Alvarez-Cermeño JC.

Biomed Res Int. 2014;2014:128517. doi: 10.1155/2014/128517. Epub 2014 Sep 18.

50.

Review of the novelties presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III).

Fernández Ó, Álvarez-Cermeño JC, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, García-Merino JA, Izquierdo G, Meca-Lallana J, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oliva-Nacarino P, Oreja-Guevara C, Prieto J, Ramió-Torrentà L, Romero-Pinel L, Saiz A, Rodríguez-Antigüedad A, Grupo Post-ECTRIMS.

Rev Neurol. 2014 Oct 16;59(8):371-9. English, Spanish.

Supplemental Content

Loading ...
Support Center